Daily Archives: January 29, 2022

By Dr. Sanchit Sharma,

As Ayurveda takes over the world as an alternate system of treatment and medication, the Ayurveda sector in India eyes the Union Budget 2022 for a probable push towards better Research and Development of the ancient science of life. Ayurveda has been providing holistic solutions to ailments, physical and mental, for ages, but notable progress on the science has been made only in the last decade.

With the influence of biomedicine, Ayurveda has furthered itself towards medicalization. Standardization and professionalization of Ayurveda through practice and application at the community, individuals, and healthcare providers level has further contributed to enhancing the Ayurvedic sector. Despite the progress, leveraging the Herbal, AYUSH, and the Nutraceutical Industrys domestic and export potential is yet another thing. The industrial outcome pertaining to meeting such demands may not come without a generous consideration from the government.

Ayurveda as Alternative Medicine System

The understanding of health in Ayurveda is based on adaptive feedback, which each person establishes with the environment. It is more than a biological process involving mind and body fitness. Ayurveda today has prospered as an alternative medication even for people with critical illnesses. It has largely been helpful for people with chronic debilitating conditions to take medications under conditions of critical care.

Besides mentioned properties, with the intervention of Ayurveda in routine lives, people have subscribed to the notion of enhanced immunity with regular use. The science of from the plants to the plates has effectively changed the notion of health, which was seen as the absence of disease by healthcare providers. The emphasis is instead on the constant state of living, which Ayurveda continually expands on.

Ayurveda under Governments Push

In the face of the global health crisis, the NDA government under Prime Minister Narendra Modi has propounded the idea of combating Covid-19 with the holistic human science, Ayurveda. It has commendable and wholesome therapeutic properties as a practicable alternative healthcare system. Now that we know the importance of natural immunity, the need for Ayurveda, its practice, and its application has been all the more lucid to us. In the fourth chapter of the Global Ayurveda Festival held last year, Prime Minister Narendra Modi reiterated the goodness and impact of Ayurveda and traditional medication. Mr. Modi also emphasized the importance of integrating Ayurveda with evidence-based medical science at the Festival.

Previously, the Government has undertaken popular surveys on peoples familiarity with Ayurveda through the ministry of AYUSH. Moreover, the Government has been promoting the sale of Ayurvedic medicine through Special Purpose Vehicles (SPVs) at various outlets across the country.

Budget Estimates for Ayurveda 2022

Last year, the Ayurvedic Sector requested Finance Minister Nirmala Sitharaman to announce a GST waiver on products with a license (a maximum of 5% on supplements and nil on Ayurvedic products), enabling customers to buy over-the-counter Ayurvedic medicines at lower prices. In the prior budget, the sector was anticipating that it would be focused on Research and Development and Innovation.

One of the agendas of the Association of Herbal and Nutraceutical Manufacturers of India (AHNMI) was the establishment of a cross-ministerial task force under a Joint Secretary at the Ministry of Commerce and Industry, which would also be a stepping stone to make nutraceuticals into $25 billion industry by 2030. A separate budget for the manufacture, procurement, and marketing of Ayurvedic medicine is expected in 2022. Boosting Ayurvedic medicine in line with the Atmanirbhar Bharat vision of PM Narendra Modi is also foreseen.

Conclusion

To ensure sustainability for the Ayurveda industries to compete with world leaders, the 2022 budget is a vital aspect of the sector. From the pioneers of Research in Ayurveda to healthcare providers, the 2022 budget would create a unique ecosystem that makes the science of Ayurveda more acceptable to the masses.

(The author isFounder & M.D., Ayouthveda. Views expressed are personal and do not reflect the official position or policy of the Financial Express Online.)

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

More here:

Budget 2022 expectations: Will FM Nirmala Sitharaman provide much-needed booster shot to Ayurveda Industry? - Financial Express

While most herbal teas are safe to drink, people with certain health conditions and those who take medication should check in with their doctor.

Image Credit: imtmphoto/iStock/GettyImages

If you're craving a flavorful drink without added sugar or with less caffeine, or you just aren't a coffee fan (we see you), tea is a great alternative. Whether you want something fruity like hibiscus or citrusy and floral like Earl Grey, tea boasts plenty of health benefits.

But before you start swinging cup after cup, one crucial step many people often make when drinking herbal teas is not checking in with their doctor or dietitian before introducing them into their diets.

"Many people believe that 'natural' is safer and don't consider the possibility that natural herbal teas may interact with drugs or have negative side effects for certain medical conditions like pregnancy," says Amber Trejo, RDN, dietitian and founder of Naked Wellness. "It's also important to note that herbal teas aren't regulated by the Food and Drug Administration (FDA)."

Although most herbal teas are generally considered safe in modest amounts, people who live with certain health conditions should limit or avoid some herbal teas, says Tamar Samuels, RD, CDN, co-founder of Culina Health.

For example, if you have diabetes, are taking blood thinners for stroke prevention or are on antidepressants, drinking certain herbal teas may interact with your medications. We flagged some herbal teas you should limit or avoid drinking altogether if you live with these health conditions.

Samuels recommends taking medications 2 to 3 hours apart from drinking tea if you're concerned about potential interactions. Talk to your doctor if you're unsure about specific herb-drug interactions.

Medications that have a narrow therapeutic window meaning small changes in the blood concentration of the drug can cause adverse events have a greater chance of interacting with herbal teas, Samuels explains.

"If you're taking cyclosporine (immunosuppressant), anticoagulants (blood thinners), digoxin (medication for heart failure or irregular heart rhythm) or anticonvulsive drugs, it is best to work with a healthcare provider to determine which herbal teas are safest for you."

This nighttime favorite has been used to help with sleep because it helps reduce anxiety, thanks to its mild tranquilizing effects, according to a November 2010 article in Molecular Medicine Reports.

Chamomile may also help lower blood sugar levels in people with diabetes. According to a small January 2016 study in Nutrition, short-term intake of chamomile tea has beneficial effects on glycemic control in people with type 2 diabetes.

But drinking copious amounts may significantly lower your blood sugar.

"Lowering blood sugar too much can result in a hypoglycemic event. If you are a person with diabetes, you don't have to avoid chamomile tea but should monitor your blood sugar closely should you choose to drink it. Working with a registered dietitian can help determine if or how much chamomile tea is safe for you," Samuels says.

Green tea has also been shown to interact with some medications that are used to treat heart conditions, Samuels says, so it's best to limit green tea if you are taking these medications.

"Green tea leaves (dried) contain vitamin K, which can increase blood clotting. Large amounts of vitamin K may interfere with the activity of some blood thinners, like warfarin," Dunn says.

"Lisinopril is frequently prescribed for treating hypertension and heart failure, so people taking it should limit their consumption of green tea and green tea extracts because they can decrease the effectiveness of the drug."

"Gingko tea and green tea should be avoided if you have a health condition that requires the use of blood-thinning medications, including Coumadin (warfarin), Plavix (clopidogrel), aspirin and other anticoagulants," Samuels says.

This is because ginkgo biloba slows blood clotting, and taking it in conjunction with other drugs, such as ibuprofen, naproxen or aspirin, can increase your risk of bleeding, says Brittany Dunn, RD, a sports dietitian and performance chef.

People who have epilepsy or those taking antidepressants avoid drinking ginkgo tea, Trejo notes. Taking large amounts of ginkgo may cause seizures and reduce the effectiveness of anticonvulsant drugs, per the Mayo Clinic. It might also weaken certain antidepressants, such as fluoxetine (Prozac and Sarafem) and imipramine (Tonfranil).

4. Ginseng and Licorice Teas

Just like ginkgo biloba, ginseng and licorice teas can reduce the effectiveness of anticoagulant medications including warfarin, Samuels says. Avoid these teas if you experience blood clots and have deep vein thrombosis (DVT) or other health conditions that are treated with anticoagulants.

Ginseng can also reduce the effectiveness of certain chemotherapeutic and HIV agents, calcium channel blockers, some statin medications and certain antidepressants, Dunn says.

"Calcium channel blockers are used to treat high blood pressure and may also be prescribed to mitigate symptoms of coronary artery disease, arrhythmia, angina, high cholesterol and other risk factors for cardiovascular disease," Dunn says.

St. John's wort interacts with a variety of medications, including antidepressants, birth control pills, cyclosporine, HIV drugs and blood thinners, Trejo says, so make sure to talk with your doctor before you drink teas with St. John's wort.

Although many people claim that St. John's wort can help treat depression in combination with antidepressants, the National Center for Complementary and Integrative Health says that adding St. John's wort to your depression treatment plan can lead to dangerous levels of serotonin in the body.

Link:

5 Herbal Teas That Interact With Drugs and Medications - Livestrong

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa

Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on net sales in China

CHESTERBROOK, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Chinas National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection. The NDA was submitted by Trevenas partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa of a Phase 3 bridging trial for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the Food and Drug Administration (FDA) for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

"We are pleased to see the data presented in Nhwas NDA submission are consistent with data from our registration studies in the US, said Carrie Bourdow, President and CEO of Trevena. We are confident that Nhwa is the right strategic partner to advance OLINVYK in China and believe that this collaboration has the potential to create significant value for our stakeholders over the years ahead.

Trevena executed an exclusive License Agreement in 2018 with Nhwa to develop, manufacture, and commercialize OLINVYK in China and is eligible to receive regulatory and commercial milestone payments as well a 10% royalty on net sales in China.

Nhwas submission to the NMPA included data from two clinical bridging studies in Chinese patients, based on feedback from Chinas NMPA: a dose-escalation, open-label, single-dose study to evaluate the pharmacokinetics and safety profile; and a randomized, double-blind, positive-controlled Phase 3 bridging study in subjects with moderate to severe acute pain after abdominal surgery to evaluate the analgesic efficacy and safety of OLINVYK compared with IV morphine.

The results of the Phase 3 bridging study show that the safety and pharmacokinetic profile of oliceridine in Chinese patients is consistent with the data from global studies and demonstrates safety and tolerability in Chinese populations. The launch of OLINVYK in China, if approved by the NMPA, will help to address the significant unmet need in acute pain management.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companys novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

For more information, please visit http://www.Trevena.com

About Jiangsu Nhwa Pharmaceuticals

Jiangsu Nhwa Pharmaceutical Co., Ltd., is a Chinese pharmaceutical company committed to setting new standards in CNS healthcare. Nhwa endeavors to provide innovative, high quality medicines to CNS patients with serious unmet medical needs. Nhwa offers a growing portfolio of more than 100 marketed products covering more than 6000 hospitals throughout China, including antipsychotics, anesthetics and analgesics, and neurological products. For more than 60 years, Nhwa has focused on CNS medicine, and every member of Nhwa's approximately 3,000-strong workforce is dedicated to improving patient health and outcomes.

About OLINVYK (oliceridine) injection

OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at http://www.OLINVYK.com.

Important Safety InformationWARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS

ADDICTION, ABUSE, AND MISUSE OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patients risk before prescribing OLINVYK, and monitor all patients regularly for the development of behaviors or conditions.

LIFE-THREATENING RESPIRATORY DEPRESSION Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK. Monitor for respiratory depression, especially during initiation of OLINVYK or following a dose increase.

NEONATAL OPIOID WITHDRAWAL SYNDROME Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Companys strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words anticipate, believe, estimate, expect, intend, may, plan, predict, project, suggest, target, potential, will, would, could, should, continue, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Companys clinical trials or any future trials of any of the Companys investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Companys assessment of discussions with FDA; available funding; uncertainties related to the Companys intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Companys therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Companys Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Companys views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Companys views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com(617) 430-7576

PR & Media Contact:Sasha BennettAssociate Vice PresidentClyde GroupSasha.Bennett@clydegroup.com(239) 248-3409

View post:

Trevena Announces Submission of New Drug Application in China for OLINVYK by its Partner Jiangsu Nhwa Pharmaceutical - StreetInsider.com

The registration for national-level counselling for undergraduate AYUSH courses for the academic year 202122 began on Saturday, 29 January.

Aspirants who have cleared the National Eligibility-cum-Entrance Test (Undergraduate) or NEET (UG), 2021, can register on the website http://www.aaccc.gov.in and do choice filling from Sunday, 30 January, onwards. The website is of the Ayush Admissions Central Counseling Committee.

(AYUSH is an acronym for Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy. These are the six indigenous alternative medicine systems practised in India.)

No scope for changes or editsThe candidates must note that the information that you give during the registration would be final and wouldnt get another chance to change or edit it. Applicants who register more than once would be debarred.

Four rounds of counselling There are four rounds of counselling preceding the AYUSH course admissions. They are Round 1, 2, 3 ( (mopup) and the stray vacancy round.

Aspirants may register before the first three rounds within the stipulated dates. The number of seats that are up for grabs would be less from the second round onwards.

Candidates wouldnt be eligible for admission only because they got an allotment. They should meet all the eligibility criteria to secure admission to the courses.

They need to keep in mind the unique guidelines and fee structure of each institution before applying.

The seatsThe undergraduate seats for which the counselling is being held are in the following institutions:

1)Government/aided colleges in all the states and Union Territories except Jammu and Kashmir. (The AllIndia quota is 15%.)2)100% seats in Banaras Hindu University (Ayurveda), Delhi University (Ayurveda, Unani and Homeopathy) and deemed universities (all four branches)3)100% seats except those for nominated candidates in the Institute of Teaching and Research, Jamnagar (Ayurveda); National Institute of Ayurveda, Jaipur; and National Institute of Homoeopathy, Kolkata,4) 50% in Aligarh Muslim University (Unani) and North-Eastern Institute of Ayurveda & Homoeopathy (NEIAH), Shillong (Ayurveda and Homeopathy).

The seat allotment to 15% AllIndia quota at the private institutes that arent deemed universities would be done by the state governments. All the seats at minority institutions of Jain/ Muslim/ Hindi Linguistic communities are wholly reserved for these categories.

Share of reservationReservations are available as per the guidelines of the central government1) for 15% AllIndia quota seats and at central universities and national institutes2) 15% for Scheduled Castes3) 7.5% for Scheduled Tribes4) 27% for Other Backward Classes, and5) 10% for Economically Weaker Sections.

The remaining 40.5% seats are open for the General category.

Also, 5% seats in each category are reserved for persons with disabilities.

Thiruvananthapuram Medical College is included in the list of 15 approved institutes that could issue certificates of disability.

Fee structureDeemed universities: Rs 5,000 as registration fee and Rs 50,000 as security deposit. The candidates have to pay a total of Rs 55,000. There is no waiver for any categories.

All central seats including AllIndia quota (barring deemed universities): Rs 1,000 for registration. The security deposit would be Rs 10,000. That would be a total of Rs 11,000. Meanwhile, it is Rs 500 and Rs 10,000 for Scheduled Castes/Tribes and persons with disabilities, making for a total of Rs 10,500.

The payment page would be opened as soon as you complete the registration. Fee could be paid using net banking/card.

Other guidelinesThe mobile number and the email id that were given during the application for NEET should be used for registration. A new password should be created and kept for further use. It is better to use a computer/laptop for choice filling and not a mobile phone.

The applicants can submit any number of choices.

Do not forget to lock in the choices. The choices could be re-set or re-arranged until they are locked. In case the candidate doesnt lock the choices, it would be automatically locked at the stipulated time. Then follows the processing and allotment.

Those who didnt get seats despite registering for the first round need not register in the second round. Similarly, those who didnt get any seats allotted in the first and second rounds need not re-register for the mop-up round. However, they need to do the choice filling again.

Meanwhile, there is no registration for the stray vacancy round.

Even the MCC cannot unlock the choices once they are locked in. So, the applicants need to be careful and double check before locking the choices.

Upgradation and free exitUpgradation and free exit are possible only in the first round. However, the candidates have to reach the college and join in order to retain the seat that has been allotted in the first round. They can then request for upgradation. If the upgradation is allowed, then the aspirants should strictly get a relieving letter before giving up the first seat.

Those who got a seat in the first round but didnt get an upgradation in the second round can give up the first one without losing the security deposit (free exit). However, if they didnt give up the seat within five days after the second allotment is announced, the admission in the first round would be considered as retained. Besides, the candidate wouldnt get another chance at counselling.

Those who didnt join the seat that has been allotted in the second round can choose free exit. In case they join the college, the candidate can still leave the seat until three days before the mop-up round begins. They wouldnt lose their security deposit.

However, the applicant would be considered as disqualified if he/she doesnt choose such an exit option. Then they cannot attend the AYUSH counselling anywhere including the states. The security deposit would be lost if the candidate doesnt join the college after they receive seat in the mop-up or the stray vacancy round. They would be disqualified too.

If the aspirant gets an upgradation after securing a seat in the second or the mop-up rounds, the current seat would be lost.

Those candidates who join a college after securing seat in the mop-up allotment wouldnt be considered during the state counselling.

Documents neededThe list of documents that need to be submitted while joining the college are given in the counselling bulletin (pages 21,22). However, the candidates should go through the website of the respective college or contact them directly to enquire whether they require any additional documents.

Click on the Archives link in the News & Events section on the UG counselling web page to get an idea about the scope of admission based on your position in the rank list. The category-based list of the last ranks at which the candidates got admission in 202021 would be in the website.

Helpline: 9354529990.

Read more from the original source:

AYUSH UG counselling: Registration begins; here's the checklist - Onmanorama